Innoforce Pharmaceuticals is located in the Hangzhou Airport Economic Demonstration Area. As the key enterprise in Hangzhou Bay Biotech Valley, Innoforce’s goal is to establish top-tier global development and biomanufacturing capabilities to facilitate the development and commercialization of innovative medicines. The leaders of Innoforce have stellar international track records with extensive expertise in technologies and business operations. The first phase of the Innoforce campus covers an area of nearly 21 acres with a total construction area of approximately 180,000 square meters. The campus includes biologic process development laboratories, scale-up lab, pilot facility, multiple 2000L commercial production lines, and Cell and Gene Therapy manufacturing suites.
Dr. Yuling Li is a seasoned executive with proven experience in biopharmaceutical development from clinical to commercialization. She was a R&D Director and Fellow at MedImmune/AstraZeneca and Senior Director of Purification Sciences at HGS (now GSK). She played key roles in the development of 3 approved products and contributed to over 30 clinical development programs.
In 2014, she received the Rising Star Award from the Healthcare Businesswomen’s Association. She served as the President of the Chinese Biopharmaceutical Association and co-founded the Alliance of ALL-CABPA in 2008.
Dr. Li has authored over 40 publications and is the primary inventor for seven issued patents. She received her Ph.D. from Robert Wood Johnson Medical School at Rutgers University.
Dr. Carter is a dynamic biotechnology industry executive and scientific leader with deep experience in early-stage company development. Since 2010 he has been involved in starting several biotechnology companies as a co-founder, advisor, CEO, and/or member of the Board of Directors. From 1999 until 2009, Dr. Carter was a co-founder and the CEO of Avalon Pharmaceuticals. Under his leadership, Avalon developed a pipeline of cancer drug candidates based on a novel high-throughput genomic screening technology, and completed an IPO and listing on the NASDAQ Stock Market. Earlier in his career, Dr. Carter was head of gene mapping at Human Genome Sciences, Inc. where he was involved in the discovery of dozens of novel human proteins with therapeutic or diagnostic potential, particularly for the treatment of cancer. Dr. Carter is also engaged in a range of educational and teaching activities and holds an adjunct faculty position at Johns Hopkins University, where he teaches a course entitled “Creating a Biotechnology Enterprise”.×
Zhenhua Wu received his master’s degree in Project Management in University of Queensland Australia in 2009, and joined a public real estate company in Hangzhou. During his time in the real estate industry, he managed several key projects. In 2017, Zhenhua was part of the co-founding team at Innoforce. He is responsible for Innoforce public relations and construction management affairs.×
With an MBA from CEIBS, Mr. Zhu has more than 30 years of experience in finance management, fundraising and IPO in multi-national companies, Fortune 500 companies, leading China entrepreneurial companies and financial corporations. Mr. Zhu has extensive expertise in financing, IPO, M&A, strategy, commercial operations and general management. Prior to joining, Mr. Zhu served as the CFO of Gmax BioPharm LLC, CFO and COO of Crown Bioscience International and took it to IPO on TPEx in 2016, CFO of Shanghai Chemspec International and took it to IPO on NYSE in 2009, CFO of Canadian Solar Inc. and took it to IPO on NASDAQ in 2006.×
Dr. Yingfei Wei has an extensive experience in biotechnology and pharmaceutical industry both as a scientist and as an executive. From 2006 to 2012, Dr. Wei served as the Chief Scientific Officer for 3SBio, Inc., a leading and the first NASDAQ listed Chinese bio-pharmaceutical company. From late 1998 to early 2004, Dr. Wei served as Director of Cell and Analytical Biology with the Bayer Biotech Research Division. Prior to joining Bayer, Dr. Wei was one of the founding scientists in Human Genome Sciences Inc. in Maryland. She played key role in discovery of the HPNCC gene for colon cancer, which was nominated as “The Molecule of the Year" by Science magazine in 1994. Dr. Wei received her bachelor's degree from Peking University, and PhD from UC Davis. She completed her post-doc at Harvard School of Public Health. Dr. Wei is actively involved in biopharmaceutical-related associations including CABS, CBA, and BayHelix. She is also an advocator and participant in rural area early childhood education.×
Dr. Michael Huang has extensive technical and leadership experience in Quality Operations, Biopharmaceutical Development, and CMC Management with global biopharmaceutical companies (Sanofi Pasteur, Merck, MedImmune/AstraZeneca) and global standard-setting organization (USP). He played key roles supporting the development and licensure of new vaccines (MENACTRA, GARDASIL) and new mAb-based biotherapeutics (IMFINZI, FASENRA, LUMOXITI) as well as commercial operations and market supply for several key biologics. In addition to the US, Dr. Huang has extensive experience in China and Europe, including due diligence, JV, regulatory submissions, audits, drug substance and fill finish manufacturing management. Aside from work, he is a strong advocate for US-China culture exchange and has volunteered teaching for many years at weekend local Chinese school for families with adopted children, business travelers, and other community members.
Dr. Huang received his bachelor’s degree from Fudan University in Shanghai, China, and his Ph.D. from the University of Georgia, Athens, Georgia, USA. He also did a postdoc fellowship in biological mass spectrometry at the Pacific Northwest National Laboratory (Battelle Northwest).
Dr. Zhenhong Li is an accomplished technical and quality executive with over 30 years of successful and hands-on experience in Biotechnology and Pharmaceutical Industry. She received her Ph.D. in Chemistry from Princeton University, and completed her post-doctoral training in cellular signal transductions at the National Institutes of Health and Bristol Myers Squibb. Throughout her career, she has worked at Bristol Myers Squib, Gilead Sciences, MedImmune, Baxter Biosciences, Human Genome Sciences, GSK and REGENXBIO in the fields of small molecules, nucleotides, vaccines, protein therapeutics, and gene therapy. Her expertise is not only technically driven, but also focused at strategically harnessing cross-functional talent to deliver technological advancement and effectively apply analytical technology to product characterization and support. Dr. Li has deep experience in the areas of product development, quality control operations, and the establishment of quality systems for biotech manufacturing.
Throughout Dr. Li’s career, She has contributed to the development and commercial launch of various products including Viread from Gilead; NeisVac-C from Baxter; Palivizumab (Synagis) from MedImmune, BELYSTA and Raxibacumab from HGSI, along with many clinical programs.
Robert Valdes has over 25 years of experience in the GMP Manufacturing sector and currently serves as co-founder of Biotech Resources Group (USA) and INNOASIA Ltd.(Hangzhou, PRC). Prior to BRG, Bob was Director of Large-Scale Manufacturing at Human Genome Sciences (now GSK) where he oversaw the manufacture of HGS’ first commercial product. Bob was the first manufacturing engineer hired by HGS in 2000 for their Large-Scale Manufacturing facility design effort where he was involved hands-on from Business Concept to Commercialization.
Prior to Bob’s 12-year tenure at HGS, he was employed by Lonza Biologics (US/UK) from 1994-2000 in various positions in GMP manufacturing design, start-up, and operations. Mr. Valdes holds Master’s Degrees from the University of Massachusetts and Johns Hopkins and a B.A. in Microbiology from the University of New Hampshire.
Dr. Bin Shi joined InnoForce as VP of BD in Dec. 2020. Previously she served as VP and Chief Strategy Officer for Biology and Business Development functional areas in a Chinese startup called Deuracor (now changed to TYK Medicines) during August 2018 – December 2020, when they successfully submitted 2 new drug INDs in NMPA and both approved in 2019; licensing-out the greater China right to Livzon of one of their preclinical PCC anti-cancer drugs; Leading biology team completed from 0 to 1 in Changxing Biotech Park. Before that, Bin is the SLT member of Amgen Asia R&D Center (2016 - 2018) serving as Head of External R&D and Licensing to leverage wide external scientific and technology expertise to advance and complement Amgen’s global portfolio. During those two years, they signed >20 research agreement and submitted >100 potential licensing projects in Amgen global licensing system. She was the appointed leader of Amgen matrix management system in Shanghai R&D center. Before returning to China, Bin was a Research Fellow at Merck and Schering-Plough for ~19 years (1998-2016); as an in vivo Pharmacology expertise, overseeing anti-cancer, anti-viral, neuroscience, siRNA Therapeutics and vaccine drug discovery and development projects. Bin has published more than 20 papers in reputed journals including JBC, Cancer Research etc, serving as the first and corresponding author, serving as an invited reviewer and an invited speaker and meeting chairman at several conferences. She is an invited Industry Mentor by ShanghaiTech University and Nankai University. Bin is a lifetime SAPA member, and served as President (2016-2017) of SAPA-GP; a member of BayHelix; VP and General Secretary of Shanghai Overseas Returned Scholars Association (ORSA); an active member of AACR, CSCO and other organizations. Bin completed her Ph.D. at Thomas Jefferson University in Philadelphia, her Master of Science degree at State University of New York (SUNY) in Syracuse, and her Bachelor of Science degree at Nankai University in Tianjin China.×
Mr. Goldberg is a seasoned pharmaceutical & biotechnology professional with >20 years of experience in marketing, strategy, business development and investment banking/private equity. He led the completion of a range of business development transactions including acquisitions/divestitures, JV’s, in-licensing & out-licensing partnerships, and financings. His extensive international experience includes over a decade of assignments covering China, Asia-Pacific, and Europe.
Mr. Goldberg was most recently Sr. Director of Strategy for Pfizer’s Upjohn Division where he focused on business growth & value creation. He previously served in marketing leadership roles covering Asia-Pacific & Europe regions with responsibilities for portfolios of $1-2B USD revenue in Rare Disease, CV, Pain, CNS, Urology & Women’s Health. From 2010 to 2013, Mr. Goldberg, served as head of Strategy & Business Development for Pfizer China. Mr. Goldberg joined Pfizer through the acquisition of Wyeth, where he worked in global & China focused strategy & business development roles. He previously worked at RoundTable Healthcare Partners, a private equity firm, and Bear Steans’ Investment Banking group.
Mr. Goldberg received his MBA from Kellogg School of Management with a focus on marketing & strategy. He also earned his BBA in Finance from Emory University.